NICE One Step Closer To A Fairer Deal For Prostate Cancer Patients - Men To Benefit From Equality Of Access To Chemotherapy Treatment

... Today, the National Institute of Health and Clinical Excellence (NICE) moved towards achieving equality of access for a novel chemotherapy treatment for men with metastatic hormone refractory prostate cancer (mHRPC). NICE have published their Final Appraisal Determination (FAD),[i] which recommends that all eligible men with mHRPC are given equal access to a Taxotere® (docetaxel) based regimen that has been proven to improve quality of life and extend survival... click link for more info. ...